Skip to main content

CKD

0
Pipeline Programs
8
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
1 program
FMDN/A1 trial
Active Trials
NCT05125913Unknown250Est. Mar 2024
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
FMDN/A
Medical Components
Medical ComponentsPA - Harleysville
1 program
Long term hemodialysis catheterN/A
Veeva Systems
Veeva SystemsPLEASANTON, CA
1 program
Long term hemodialysis catheterN/A
Syneos Health
Syneos HealthNC - Morrisville
1 program
Long term hemodialysis catheterN/A1 trial
Active Trials
NCT04782297Withdrawn0Est. Mar 2023
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
Renalive® LP, flavour VanillaN/A1 trial
Active Trials
NCT06892249Completed74Est. Apr 2026
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
vicadrostat / empagliflozin combination 1PHASE_21 trial
Active Trials
NCT07304817Recruiting100Est. Feb 2028
Renibus Therapeutics
Renibus TherapeuticsTX - Southlake
1 program
VeverimerPHASE_31 trial
Active Trials
NCT07355062Recruiting150Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Renibus TherapeuticsVeverimer
Boehringer Ingelheimvicadrostat / empagliflozin combination 1
Fresenius KabiRenalive® LP, flavour Vanilla
Syneos HealthLong term hemodialysis catheter
Innovation PharmaceuticalsFMD

Clinical Trials (5)

Total enrollment: 574 patients across 5 trials

A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

Start: Jan 2026Est. completion: Jun 2027150 patients
Phase 3Recruiting
NCT07304817Boehringer Ingelheimvicadrostat / empagliflozin combination 1

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

Start: Apr 2026Est. completion: Feb 2028100 patients
Phase 2Recruiting
NCT06892249Fresenius KabiRenalive® LP, flavour Vanilla

Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Outpatients in Taiwan

Start: Jun 2025Est. completion: Apr 202674 patients
N/ACompleted
NCT04782297Syneos HealthLong term hemodialysis catheter

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

Start: Mar 2022Est. completion: Mar 20230
N/AWithdrawn

Long Term Cardio-Vascular Risk Assessment in CKD and Kidney Transplanted Patients Following SARS-COV-2

Start: Jan 2021Est. completion: Mar 2024250 patients
N/AUnknown

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 574 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.